Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

By LabMedica International staff writers
Posted on 06 Mar 2025

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around 69,120 new cases will be diagnosed, with approximately 13,860 deaths resulting from the disease. While immunotherapy plays a significant role in treatment, it is not effective for all patients, and many experience a recurrence of the cancer. However, researchers have made a key discovery that could guide doctors in selecting more effective treatments for patients with recurrent endometrial cancer. Their study, published in the Journal for ImmunoTherapy of Cancer (JITC), identified specific proteins in the blood (biomarkers) that might predict how well a patient will respond to a combination of two cancer drugs, cabozantinib and nivolumab.

This study, conducted by scientists at the Icahn School of Medicine at Mount Sinai (New York, NY, USA), is the first to explore blood markers that could aid in personalizing treatment and improving patient outcomes. The team discovered that certain proteins in the blood exhibited different behaviors in patients receiving nivolumab alone versus those on the combination therapy. Patients who had lower levels of specific proteins linked to macrophages (a type of white blood cell critical to the immune system) prior to treatment responded more favorably to the drug combination. Additionally, some patients showed particular immune activation markers, which helped enhance their cancer-fighting response, resulting in longer survival.

The study also found that elevated levels of proteins associated with neutrophils (another type of white blood cell involved in the immune response) were connected to increased side effects from the treatment. Importantly, the combination therapy proved effective for some patients who had previously stopped responding to other treatments. If these findings are validated in future studies, doctors may be able to use a simple blood test to predict whether a patient is likely to benefit from this treatment, thereby avoiding unnecessary therapies and focusing on the options most likely to succeed.

"Our research provides new insights into how the immune system responds to cancer treatment," said lead researcher Sacha Gnjatic, PhD, Professor of Immunology and Immunotherapy in The Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai. "By identifying specific biomarkers in the blood, we can better predict which patients will benefit from combination therapy, allowing for more personalized and effective treatment strategies. This approach has the potential to improve survival rates while minimizing side effects, ultimately advancing the field of cancer immunotherapy."

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HbA1c Test
HbA1c Rapid Test
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.